Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report
Received 7 September 2017
Accepted for publication 16 January 2018
Published 23 April 2018 Volume 2018:11 Pages 2303—2309
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Faris Farassati
Hua Duan,1 Yanmei Peng,1 Huijuan Cui,2 Yuqin Qiu,1 Qiang Li,1 Jingyi Zhang,1 Wen Shen,1 Chenyao Sun,1 Chufan Luo1
1Department of China–Japan Friendship Hospital, Beijing University of Chinese Medicine, Beijing, China; 2Department of Oncology, China–Japan Friendship Hospital, Chaoyang, Beijing, China
Abstract: Epidermal growth factor receptor-tyrosine kinase inhibitors have improved progression-free survival and overall survival in non-small-cell lung cancer (NSCLC) patients with sensitive mutations. However, response of uncommon mutation to epidermal growth factor receptor-tyrosine kinase inhibitors is still unclear. S768I is one of the uncommon mutations.
A female patient with advanced NSCLC with a single S768I mutation achieved effectiveness from afatinib after showing no response to gefitinib. The patient had progression-free survival after taking afatinib for 6 months, and her follow-up is continuing. It suggests that afatinib may be a more effective treatment for NSCLC patients with a single S768I mutation, compared to first-generation tyrosine kinase inhibitors.
Keywords: NSCLC, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), S768I, afatinib, gefitinib
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]